Digoxin

Generic Name: Digoxin

Brand Names: Digox, Lanoxin

Drug Type: Small Molecule

Chemical Formula: C_₄₁H_₆₄O_₁₄

CAS Number: 20830-75-5

Unique Ingredient Identifier: 73K4184T59

Background: Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.
...

Indication: Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients. 2) To increase myocardial contraction in children diagnosed with heart failure. 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.
...

Associated Conditions: Myocardial contractility, Ventricular Arrhythmia, Mild to moderate heart failure

Associated Therapies: -

Clinical Trials

Pharmacokinetics, Safety and Tolerability of Digoxin With or Without Co-administration of BI 1356 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Digoxin
Drug: BI 1356

First Posted Date: 2014-07-08

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02183402

Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 201335 NA
Drug: Caffeine
Drug: Warfarin sodium
Drug: Vitamin K
Drug: Omeprazole
Drug: Dextromethorphan hydrobromide
Drug: Midazolam HCl solution
Drug: Midazolam HCl oral syrup
Drug: Digoxin

First Posted Date: 2014-07-08

Last Posted Date: 2014-07-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 23

Registration Number: NCT02182336

The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin

Phase 1

Completed

Conditions: Epilepsy

Interventions: Drug: Placebo
Drug: BIA 2-093
Drug: Digoxin

First Posted Date: 2014-06-24

Last Posted Date: 2014-12-31

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 13

Registration Number: NCT02172742

Locations: 🇵🇹
Human Pharmacology Unit (UFH)Section of Clinical Research (SIC), Department of Research & Development (DID), BIAL - Portela & Cª, SA,, Mamede do Coronado, Portugal

Relative Bioavailability of Dabigatran and Digoxin in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dabigatran etexilate
Drug: Digoxin

First Posted Date: 2014-06-23

Last Posted Date: 2014-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02171052

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects

Phase 1

Completed

Conditions: Drug-Drug Interaction (DDI)
Pharmacokinetics
Healthy Subjects

Interventions: Drug: Mirabegron
Drug: Solifenacin
Drug: Digoxin

First Posted Date: 2014-04-30

Last Posted Date: 2014-07-11

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 26

Registration Number: NCT02127034

Locations: 🇩🇪
Parexel International GmbH, Berlin, Germany

A Preliminary Drug Drug Interaction Study With TA-8995

Phase 1

Completed

Conditions: Pharmacokinetic Interactions

Interventions: Drug: TA-8995
Drug: Digoxin
Drug: Midazolam

First Posted Date: 2014-04-28

Last Posted Date: 2016-10-03

Lead Sponsor: Xention Ltd

Target Recruit Count: 18

Registration Number: NCT02124954

Locations: 🇬🇧
Covance, Leeds, United Kingdom

Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Digoxin
Drug: Rosuvastatin
Drug: Regorafenib (Stivarga, BAY73-4506)

First Posted Date: 2014-04-08

Last Posted Date: 2019-06-07

Lead Sponsor: Bayer

Target Recruit Count: 42

Registration Number: NCT02106845

A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: E2609
Drug: itraconazole
Drug: rifampin
Drug: digoxin
Drug: donepezil

First Posted Date: 2014-02-05

Last Posted Date: 2015-11-03

Lead Sponsor: Eisai Inc.

Target Recruit Count: 195

Registration Number: NCT02055703

Locations: 🇺🇸
WCT Early Development, San Antonio, Texas, United States

Digoxin Versus Ivabradine in Heart Failure With Reduced Ejection Fraction

Phase 4

Conditions: Heart Failure

Interventions: Drug: Ivabradine
Drug: Digoxin

First Posted Date: 2014-01-27

Last Posted Date: 2014-01-27

Lead Sponsor: Kocaeli University

Target Recruit Count: 60

Registration Number: NCT02046044

Locations: 🇹🇷
Kocaeli University, Kocaeli, Turkey

A Study of Evacetrapib and Digoxin in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Digoxin
Drug: Evacetrapib

First Posted Date: 2013-07-12

Last Posted Date: 2018-10-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 16

Registration Number: NCT01897493

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy